PMID- 28720165
OWN - NLM
STAT- MEDLINE
DCOM- 20180612
LR  - 20180816
IS  - 1741-203X (Electronic)
IS  - 1041-6102 (Linking)
VI  - 29
IP  - 11
DP  - 2017 Nov
TI  - BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term 
      changes in episodic memory and hippocampal volume but not serum mBDNF.
PG  - 1825-1834
LID - 10.1017/S1041610217001284 [doi]
AB  - BACKGROUND: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism 
      Met allele exacerbates amyloid (Abeta) related decline in episodic memory (EM) and 
      hippocampal volume (HV) over 36-54 months in preclinical Alzheimer's disease 
      (AD). However, the extent to which Abeta+ and BDNF Val66Met is related to 
      circulating markers of BDNF (e.g. serum) is unknown. We aimed to determine the 
      effect of Abeta and the BDNF Val66Met polymorphism on levels of serum mBDNF, EM, and 
      HV at baseline and over 18-months. METHODS: Non-demented older adults (n = 446) 
      underwent Abeta neuroimaging and BDNF Val66Met genotyping. EM and HV were assessed 
      at baseline and 18 months later. Fasted blood samples were obtained from each 
      participant at baseline and at 18-month follow-up. Abeta PET neuroimaging was used 
      to classify participants as Abeta- or Abeta+. RESULTS: At baseline, Abeta+ adults showed 
      worse EM impairment and lower serum mBDNF levels relative to Abeta- adults. BDNF 
      Val66Met polymorphism did not affect serum mBDNF, EM, or HV at baseline. When 
      considered over 18-months, compared to Abeta- Val homozygotes, Abeta+ Val homozygotes 
      showed significant decline in EM and HV but not serum mBDNF. Similarly, compared 
      to Abeta+ Val homozygotes, Abeta+ Met carriers showed significant decline in EM and HV 
      over 18-months but showed no change in serum mBDNF. CONCLUSION: While allelic 
      variation in BDNF Val66Met may influence Abeta+ related neurodegeneration and memory 
      loss over the short term, this is not related to serum mBDNF. Longer follow-up 
      intervals may be required to further determine any relationships between serum 
      mBDNF, EM, and HV in preclinical AD.
FAU - Lim, Yen Ying
AU  - Lim YY
AD  - The Florey Institute,The University of Melbourne,Parkville,Victoria,Australia.
FAU - Rainey-Smith, Stephanie
AU  - Rainey-Smith S
AD  - Centre of Excellence for Alzheimer's Disease Research and Care,Edith Cowan 
      University,Joondalup,Western Australia,Australia.
FAU - Lim, Yoon
AU  - Lim Y
AD  - School of Pharmacy and Medical Sciences,University of South 
      Australia,Adelaide,South Australia,Australia.
FAU - Laws, Simon M
AU  - Laws SM
AD  - Centre of Excellence for Alzheimer's Disease Research and Care,Edith Cowan 
      University,Joondalup,Western Australia,Australia.
FAU - Gupta, Veer
AU  - Gupta V
AD  - Centre of Excellence for Alzheimer's Disease Research and Care,Edith Cowan 
      University,Joondalup,Western Australia,Australia.
FAU - Porter, Tenielle
AU  - Porter T
AD  - Centre of Excellence for Alzheimer's Disease Research and Care,Edith Cowan 
      University,Joondalup,Western Australia,Australia.
FAU - Bourgeat, Pierrick
AU  - Bourgeat P
AD  - Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative 
      Health National Research Flagship,Australian e-Health Research 
      Centre-BiaMedIA,Brisbane,Queensland,Australia.
FAU - Ames, David
AU  - Ames D
AD  - Academic Unit for Psychiatry of Old Age,St. Vincent's Health,The University of 
      Melbourne,Kew,Victoria,Australia.
FAU - Fowler, Christopher
AU  - Fowler C
AD  - The Florey Institute,The University of Melbourne,Parkville,Victoria,Australia.
FAU - Salvado, Olivier
AU  - Salvado O
AD  - Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative 
      Health National Research Flagship,Australian e-Health Research 
      Centre-BiaMedIA,Brisbane,Queensland,Australia.
FAU - Villemagne, Victor L
AU  - Villemagne VL
AD  - The Florey Institute,The University of Melbourne,Parkville,Victoria,Australia.
FAU - Rowe, Christopher C
AU  - Rowe CC
AD  - Department of Nuclear Medicine and Centre for PET,Austin 
      Health,Heidelberg,Victoria,Australia.
FAU - Masters, Colin L
AU  - Masters CL
AD  - The Florey Institute,The University of Melbourne,Parkville,Victoria,Australia.
FAU - Zhou, Xin Fu
AU  - Zhou XF
AD  - School of Pharmacy and Medical Sciences,University of South 
      Australia,Adelaide,South Australia,Australia.
FAU - Martins, Ralph N
AU  - Martins RN
AD  - Centre of Excellence for Alzheimer's Disease Research and Care,Edith Cowan 
      University,Joondalup,Western Australia,Australia.
FAU - Maruff, Paul
AU  - Maruff P
AD  - The Florey Institute,The University of Melbourne,Parkville,Victoria,Australia.
LA  - eng
PT  - Journal Article
DEP - 20170719
PL  - England
TA  - Int Psychogeriatr
JT  - International psychogeriatrics
JID - 9007918
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/blood/diagnostic imaging/*genetics
MH  - Brain-Derived Neurotrophic Factor/blood/*genetics
MH  - Female
MH  - Genotype
MH  - Hippocampus/*diagnostic imaging
MH  - Humans
MH  - Male
MH  - *Memory, Episodic
MH  - Middle Aged
MH  - Neuroimaging
MH  - Neuropsychological Tests
MH  - Polymorphism, Genetic
MH  - Positron-Emission Tomography
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - brain-derived neurotrophic factor
OT  - hippocampal volume
OT  - memory
EDAT- 2017/07/20 06:00
MHDA- 2018/06/13 06:00
CRDT- 2017/07/20 06:00
PHST- 2017/07/20 06:00 [pubmed]
PHST- 2018/06/13 06:00 [medline]
PHST- 2017/07/20 06:00 [entrez]
AID - S1041610217001284 [pii]
AID - 10.1017/S1041610217001284 [doi]
PST - ppublish
SO  - Int Psychogeriatr. 2017 Nov;29(11):1825-1834. doi: 10.1017/S1041610217001284. 
      Epub 2017 Jul 19.